Formosa Pharmaceuticals News
Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital
April 16, 2021 Formosa Pharmaceuticals (FP), a subsidiary of Formosa Laboratories (TWSE 4746), has successfully completed a Series C financing round, increasing its cash capital …
APP13007 completes Phase 2 clinical trial and EOP2 meeting.
Formosa Pharmaceuticals and AimMax Therapeutics report top-line results from a Phase 2 clinical trial of APP13007 for the treatment of inflammation and pain after cataract …
